About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 159124, 9 pages
http://dx.doi.org/10.1155/2013/159124
Review Article

Obstetrical Antiphospholipid Syndrome: From the Pathogenesis to the Clinical and Therapeutic Implications

1Laboratory of Hormonology, Maternity, Geneva University Hospitals, 1211 Geneva 14, Switzerland
2Haemostasis Unit, Geneva University Hospitals, 1211 Geneva 14, Switzerland

Received 13 May 2013; Accepted 8 July 2013

Academic Editor: Guixiu Shi

Copyright © 2013 T. Marchetti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Costedoat-Chalumeau, G. Guettrot-Imbert, V. Leguern et al., “Pregnancy and antiphospholipid syndrome,” Revue de Medecine Interne, vol. 33, no. 4, pp. 209–216, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Danza, G. Ruiz-Irastorza, and M. Khamashta, “Antiphospohlipid syndrome in obstetrics,” Best Practice and Research: Clinical Obstetrics and Gynaecology, vol. 26, no. 1, pp. 65–76, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. J. C. Gris, S. Bouvier, N. Molinari et al., “Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study,” Blood, vol. 119, no. 11, pp. 2624–2632, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Le Thi Thuong, N. Tieulié, N. Costedoat et al., “The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 in 15 women,” Annals of the Rheumatic Diseases, vol. 64, no. 2, pp. 273–278, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Cervera, J. Piette, J. Font et al., “Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients,” Arthritis and Rheumatism, vol. 46, no. 4, pp. 1019–1027, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. R. H. W. M. Derksen and P. G. de Groot, “The obstetric antiphospholipid syndrome,” Journal of Reproductive Immunology, vol. 77, no. 1, pp. 41–50, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. R. S. Rai, L. Regan, K. Clifford et al., “Antiphospholipid antibodies and β2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach,” Human Reproduction, vol. 10, no. 8, pp. 2001–2005, 1995. View at Scopus
  9. P. G. de Groot and J. C. M. Meijers, “β2-Glycoprotein I: evolution, structure and function,” Journal of Thrombosis and Haemostasis, vol. 9, no. 7, pp. 1275–1284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. P. G. de Groot, J. C. M. Meijers, and R. T. Urbanus, “Recent developments in our understanding of the antiphospholipid syndrome,” International Journal of Laboratory Hematology, vol. 34, no. 3, pp. 223–231, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. P. L. Meroni, N. Di Simone, C. Testoni, M. D'Asta, B. Acaia, and A. Caruso, “Antiphospholipid antibodies as cause of pregnancy loss,” Lupus, vol. 13, no. 9, pp. 649–652, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. B. E. Harper, R. Willis, and S. S. Pierangeli, “Pathophysiological mechanisms in antiphospholipid syndrome,” International Journal of Clinical Rheumatology, vol. 6, no. 2, pp. 157–171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Di Simone, F. Di Nicuolo, S. D'Ippolito et al., “Antiphospholipid antibodies affect human endometrial angiogenesis,” Biology of Reproduction, vol. 83, no. 2, pp. 212–219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. S. D'Ippolito, R. Marana, F. Di Nicuolo et al., “Effect of low molecular weight heparins (LMWHs) on antiphospholipid antibodies (aPL)—mediated inhibition of endometrial angiogenesis,” PLoS ONE, vol. 7, no. 1, Article ID e29660, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. D. W. Branch, R. M. Silver, J. L. Blackwell, J. C. Reading, and J. R. Scott, “Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience,” Obstetrics and Gynecology, vol. 80, no. 4, pp. 614–620, 1992. View at Scopus
  16. A. Broder and C. Putterman, “Hydroxychloroquine use is associated with lower odds of persistant positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus,” Journal of Rheumatology, vol. 40, no. 1, pp. 30–33, 2013. View at Publisher · View at Google Scholar
  17. P. M. Izmirly, M. Y. Kim, C. Llanos et al., “Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine,” Annals of the Rheumatic Diseases, vol. 69, no. 10, pp. 1827–1830, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Galarza-Maldonado, M. R. Kourilovitch, O. M. Pérez-Fernández et al., “Obstetric antiphospholipid syndrome,” Autoimmunity Reviews, vol. 11, no. 4, pp. 288–295, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Cervera, M. A. Khamashta, Y. Shoenfeld et al., “Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients,” Annals of the Rheumatic Diseases, vol. 68, no. 9, pp. 1428–1432, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Ruffatti, A. Calligaro, A. Hoxha et al., “Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome,” Arthritis Care and Research, vol. 62, no. 3, pp. 302–307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. V. Pengo, A. Banzato, E. Bison, A. Bracco, G. Denas, and A. Ruffatti, “What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?” Seminars in Thrombosis and Hemostasis, vol. 38, no. 4, pp. 322–327, 2012. View at Publisher · View at Google Scholar
  22. J. Nodler, S. R. Moolamalla, E. M. Ledger, B. S. Nuwayhid, and Z. D. Mulla, “Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset,” BMC Pregnancy and Childbirth, vol. 9, article 11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. J. A. Gómez-Puerta, J. Sanin-Blair, and C. Galarza-Maldonado, “Pregnancy and catastrophic antiphospholipid syndrome,” Clinical Reviews in Allergy and Immunology, vol. 36, no. 2-3, pp. 85–90, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. K. L. Buckingham and L. W. Chamley, “A critical assessment of the role of antiphospholipid antibodies in infertility,” Journal of Reproductive Immunology, vol. 80, no. 1-2, pp. 132–145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. D. Hornstein, O. K. Davis, J. B. Massey, R. J. Paulson, and J. A. Collins, “Antiphospholipid antibodies and in vitro fertilization success: a meta-analysis,” Fertility and Sterility, vol. 73, no. 2, pp. 330–333, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Sanmarco, N. Bardin, L. Camoin et al., “Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization,” Annals of the New York Academy of Sciences, vol. 1108, pp. 457–465, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Mekinian, E. Lachassine, P. Nicaise-Roland et al., “European registry of babies born to mothers with antiphospholipid syndrome,” Annals of the Rheumatic Diseases, vol. 72, pp. 217–222, 2013.
  28. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators and Centers for Disease Control and Prevention, “Prevalence of Autism spectrum disorders—Autism and developmental disabilities monitoring network, 14 Sites, United States, 2008,” Morbidity and Mortality Weekly Report, vol. 61, no. 3, pp. 1–19, 2012. View at Scopus
  29. B. Giannakopoulos and S. A. Krilis, “The pathogenesis of antiphospholipid syndrome,” The New England Journal of Medicine, vol. 368, no. 11, pp. 1033–1044, 2013. View at Publisher · View at Google Scholar
  30. D. Evain-Brion, J. Guibourdenche, V. Tsatsaris, and T. Fournier, “Human trophoblast differentiation,” Bulletin de l'Academie Nationale de Medecine, vol. 193, no. 5, pp. 1017–1025, 2009. View at Scopus
  31. M. Mahler, G. L. Norman, P. L. Meroni, and M. Khamashta, “Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome,” Autoimmunity Reviews, vol. 12, no. 2, pp. 313–317, 2012. View at Publisher · View at Google Scholar
  32. P. G. de Groot and R. T. Urbanus, “The significance of autoantibodies against β2-glycoprotein I,” Blood, vol. 120, no. 2, pp. 266–274, 2012. View at Publisher · View at Google Scholar
  33. B. de Laat, V. Pengo, I. Pabinger et al., “The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study,” Journal of Thrombosis and Haemostasis, vol. 7, no. 11, pp. 1767–1773, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. T. van Horn, C. Craven, K. Ward, D. W. Branch, and R. M. Silver, “Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipis-like syndromes,” Placenta, vol. 25, no. 7, pp. 642–648, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Skrzypczak, P. Jasiński, P. Wirstlein, T. Goździewicz, and M. Rajewski, “Histologic changes in placenta and chorion of women with antiphospholipid syndrome and inherited thrombophilia,” Ginekologia Polska, vol. 82, no. 9, pp. 652–663, 2011. View at Scopus
  36. J. M. Shamonki, J. E. Salmon, E. Hyjek, and R. N. Baergen, “Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies,” The American Journal of Obstetrics and Gynecology, vol. 196, no. 2, pp. 167.e1–167.e5, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. I. Cavazzana, N. Manuela, C. Irene et al., “Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?” Journal of Autoimmunity, vol. 28, no. 2-3, pp. 160–164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Gerosa, V. de Angelis, L. Tresoidi, et al., “Complement involvement in antiphospholipid antibody-mediated placental damage: prospective study in APS pregnant women,” Annals of the Rheumatic Diseases, vol. 68, no. S3, article 210, 2009.
  39. D. Cohen, A. Buurma, N. N. Goemaere et al., “Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss,” Journal of Pathology, vol. 225, no. 4, pp. 502–511, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Girardi, J. Berman, P. Redecha et al., “Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome,” Journal of Clinical Investigation, vol. 112, no. 11, pp. 1644–1654, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Kawai and S. Akira, “Toll-like receptors and their crosstalk with other innate receptors in infection and immunity,” Immunity, vol. 34, no. 5, pp. 637–650, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Satta, E. K. O. Kruithof, G. Reber, and P. de Moerloose, “Induction of TLR2 expression by inflammatory stimuli is required for endothelial cell responses to lipopeptides,” Molecular Immunology, vol. 46, no. 1, pp. 145–157, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Dunoyer-Geindre, P. de Moerloose, B. Galve-de Rochemonteix, G. Reber, and E. K. O. Kruithof, “NFκB is an essential intermediate in the activation of endothelial cells by anti-β2-glycoprotein 1 antibodies,” Thrombosis and Haemostasis, vol. 88, no. 5, pp. 851–857, 2002. View at Scopus
  44. E. Raschi, C. Testoni, D. Bosisio et al., “Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies,” Blood, vol. 101, no. 9, pp. 3495–3500, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Vega-Ostertag, K. Casper, R. Swerlick, D. Ferrara, E. N. Harris, and S. S. Pierangeli, “Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies,” Arthritis and Rheumatism, vol. 52, no. 5, pp. 1545–1554, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Satta, S. Dunoyer-Geindre, G. Reber et al., “The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies,” Blood, vol. 109, no. 4, pp. 1507–1514, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Satta, E. K. O. Kruithof, C. Fickentscher et al., “Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies,” Blood, vol. 117, no. 20, pp. 5523–5531, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Poulton, A. Rahman, and I. Giles, “Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review,” Seminars in Arthritis and Rheumatism, vol. 41, no. 5, pp. 720–736, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Prinz, N. Clemens, D. Strand et al., “Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells,” Blood, vol. 118, no. 8, pp. 2322–2332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. M. J. Mulla, J. J. Brosens, L. W. Chamley et al., “Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway,” The American Journal of Reproductive Immunology, vol. 62, no. 2, pp. 96–111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. P. L. Meroni, M. Gerosa, E. Raschi, S. Scurati, C. Grossi, and M. O. Borghi, “Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss,” Clinical Reviews in Allergy and Immunology, vol. 34, no. 3, pp. 332–337, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. P. L. Meroni, M. O. Borghi, E. Raschi, and F. Tedesco, “Pathogenesis of antiphospholipid syndrome: understanding the antibodies,” Nature Reviews Rheumatology, vol. 7, no. 6, pp. 330–339, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. P. L. Meroni, F. Tedesco, M. Locati et al., “Anti-phospholipid antibody mediated fetal loss: Still an open question from a pathogenic point of view,” Lupus, vol. 19, no. 4, pp. 453–456, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. M. J. Mulla, K. Myrtolli, J. J. Brosens et al., “Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity,” The American Journal of Reproductive Immunology, vol. 63, no. 5, pp. 339–348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Jovanović, M. Božić, T. Kovačević, L. Radojčić, M. Petronijević, and L. Vićovac, “Effects of anti-phospholipid antibodies on a human trophoblast cell line (HTR-8/SVneo),” Acta Histochemica, vol. 112, no. 1, pp. 34–41, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. R. R. Adler, A. K. Ng, and N. S. Rote, “Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR,” Biology of Reproduction, vol. 53, no. 4, pp. 905–910, 1995. View at Publisher · View at Google Scholar · View at Scopus
  57. N. Di Simone, E. Raschi, C. Testoni et al., “Pathogenic role of anti-β2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of β2-glycoprotein I binding to trophoblast cells and functional effects of anti-β2- glycoprotein I antibodies in vitro,” Annals of the Rheumatic Diseases, vol. 64, no. 3, pp. 462–467, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Francis, R. Rai, N. J. Sebire et al., “Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome,” Molecular Human Reproduction, vol. 12, no. 7, pp. 435–442, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Andreoli, C. Bazzani, M. Taraborelli et al., “Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges,” Autoimmunity Reviews, vol. 10, no. 1, pp. 51–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. S. M. Bates, I. A. Greer, S. Middeldorp, D. L. Veenstra, A. Prabulos, and P. O. Vandvik, “VTE, thrombophilia, antithrombotic therapy, and pregnancy—antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2, supplement, pp. e691S–e736S, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Bramham, B. J. Hunt, S. Germain et al., “Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome,” Lupus, vol. 19, no. 1, pp. 58–64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. W. H. Kutteh, “Antiphospholipid antibodies and reproduction,” Journal of Reproductive Immunology, vol. 35, no. 2, pp. 151–171, 1997. View at Publisher · View at Google Scholar · View at Scopus
  63. S. M. Nelson and I. A. Greer, “The potential role of heparin in assisted conception,” Human Reproduction Update, vol. 14, no. 6, pp. 623–645, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Nishino, T. Takagi, N. Mitsuda et al., “Effect of low-dose aspirin therapy on utero-placental blood flow and malondialdehyde (MDA) as an indicator of its therapeutic effect,” Acta Obstetrica et Gynaecologica Japonica, vol. 42, no. 12, pp. 1641–1647, 1990. View at Scopus
  65. P. Fishman, E. Falach-Vaknine, R. Zigelman et al., “Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3,” Journal of Clinical Investigation, vol. 91, no. 4, pp. 1834–1837, 1993. View at Scopus
  66. J. Kwak-Kim, L. Socorro, M. Agcaoili et al., “Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome,” The American Journal of Reproductive Immunology, vol. 69, no. 6, pp. 569–607, 2013. View at Publisher · View at Google Scholar
  67. J. Alijotas-Reig, “Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management,” Lupus, vol. 22, no. 1, pp. 6–17, 2013.
  68. C. Comarmond and P. Cacoub, “Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies,” Autoimmunity Reviews, vol. 12, no. 7, pp. 752–757, 2012. View at Publisher · View at Google Scholar
  69. K. Sperber, C. Hom, C. Chao, D. Shapiro, and J. Ash, “Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases,” Pediatric Rheumatology, vol. 7, article 9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. J. H. Rand, X. Wu, A. S. Quinn, P. P. Chen, J. J. Hathcock, and D. J. Taatjes, “Hydroxychloroquine directly reduces the bindin of antiphospholipid antibody-β2-glycoprotein I complexes to phospholipid bilayers,” Blood, vol. 112, no. 5, pp. 1687–1695, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. J. H. Rand, X. X. Wu, A. S. Quinn et al., “Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug,” Blood, vol. 115, no. 11, pp. 2292–2299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. A. A. Mehdi, I. Uthman, and M. Khamashta, “Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future,” European Journal of Clinical Investigation, vol. 40, no. 5, pp. 451–464, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. R. A. Asherson, “Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome,” Immunobiology, vol. 210, no. 10, pp. 727–733, 2005. View at Publisher · View at Google Scholar · View at Scopus